Anti-Inflammatory Biologics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, and Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI102733

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 5.9% from 2023-2030
Unit	Value (USD billion)
Segmentation	By Drug Class Anti-Tumor Necrosis Factor (TNF) Interleukins Antagonists Janus Kinase (JAK) Inhibitors Others
	By Application Rheumatoid Arthritis Psoriasis Others
	By Route of Administration Oral Injection Intravenous Subcutaneous
	By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy
	By Geography North America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country) U.S. Canada Europe (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region) U.K. Germany France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region) Japan China India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, By Application, By Route of Administration, By Distribution Channel, and by Country/Sub-region) GCC South Africa Rest of Middle East & Africa